08:20 AM EDT, 07/28/2025 (MT Newswires) -- Adaptimmune Therapeutics ( ADAP ) said Monday it has agreed to sell its cell therapy programs, Tecelra, lete-cel, afami-cel, and uza-cel to US WorldMeds for $55 million in cash upfront, with potential milestone payments of up to $30 million.

The company said the deal includes all related intellectual property necessary to manufacture and commercialize the assigned assets and non-exclusively licensed intellectual property rights in its vector manufacturing process.

Employees working on the therapies will be offered roles at US WorldMeds, the company said, adding that the deal, expected to close by the end of the week, is backed by financing from Oaktree Capital and Athyrium.

Adaptimmune plans to restructure post-sale and focus on its PRAME and CD70 T-cell therapy programs.

Adaptimmune shares were more than 46% lower in premarket trading.